Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of February 2019, specifically dated February 1, 2019. The company is a clinical-stage biopharmaceutical firm headquartered in Montrouge, France, with offices in the United States. It is developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform designed to treat food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a press release announcing a corporate event rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document.
Guidance, Outlook, and Management Commentary
- Upcoming Event: CEO Daniel Tassé is scheduled to present at the 8th Annual Leerink Partners Global Healthcare Conference in New York on February 28, 2019, at 10:30 am EST.
- Access: A live webcast and a replay (available within three hours) will be hosted on the company's Investor Relations website.
- Development Pipeline: The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis.
- Market Presence: Ordinary shares trade on Euronext Paris (Ticker: DBV), and ADSs trade on the Nasdaq Global Select Market (Ticker: DBVT).
Key Facts for Investor Verification
- Verify the date and time of the Leerink Partners presentation (February 28, 2019, 10:30 am EST).
- Confirm the availability of the webcast replay on the official DBV Technologies website.
- Review the latest financial results in the most recent Form 20-F or quarterly reports, as this filing contains no financial data.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk for updates on regulatory milestones.